Skip to main content
. 2023 Feb 27;11:11. doi: 10.1038/s41413-023-00246-z

Fig. 6.

Fig. 6

The main process used to generate ex vivo DC vaccines. Progenitor cells are extracted from patients via dialysis, induced to transition into mature DCs, and then loaded with tumor antigens for administration to patients. Tumor antigen-specific T lymphocytes are activated by injected antigen-loaded DCs to exert an antitumor effect